- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03136185
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543), administered orally once daily in participants with myelofibrosis.
The primary hypothesis is that bomedemstat is a safe and tolerable orally available agent when administered to participants with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera-myelofibrosis (PPVMF), and post-essential thrombocythaemia-myelofibrosis (PET-MF) (collectively referred to as 'MF'); inhibition of LSD1 by bomedemstat will reduce spleen size in those with splenomegaly, improve haematopoiesis and reduce constitutional symptoms associated with these disorders.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia
- Royal Adelaide Hospital
-
-
-
-
-
Essen, Germany, 45147
- Universitätsklinikum Essen
-
-
-
-
-
Florence, Italy
- Azienda Ospedaliero Universitaria Careggi
-
-
-
-
-
London, United Kingdom
- Guy's and St Thomas' Hospitals
-
-
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- >18 years of age
- Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, or PPV-MF or PET-MF per the International Working Group for Myelofibrosis Research and Treatment
- High or intermediate-2 risk disease
Exclusion Criteria:
- Receiving other treatments for the condition (with exceptions and time limits)
- Major surgery in last 4 weeks, any surgery in the last 2 weeks
- History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of Screening
- History of splenectomy
- Current use of prohibited medications
- A concurrent second active and nonstable malignancy
- Known human immunodeficiency virus infection or active Hepatitis B or Hepatitis C virus infection
- Other hematologic/biochemistry requirements, as per protocol
- Use of an investigational agent within last 14 days
- Pregnant or lactating females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d
In the Phase 1/2a portion of the study, PMF participants received 0.25 mg/kg/d bomedemstat orally every day (qd) for 85 days during the Initial Treatment Period (ITP).
Qualifying participants could continue to receive treatment for an additional 85 days during an Additional Treatment Period (ATP) as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
Experimental: Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d
In the Phase 1/2a portion of the study, PPV-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP.
Qualifying participants could continue to receive treatment for an additional 85 days during an ATP as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
Experimental: Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d
In the Phase 1/2a portion of the study, PET-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP.
Qualifying participants could continue to receive treatment for an additional 85 days during an ATP as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
Experimental: Ph 2b PMF: Bomedemstat 0.5 mg/kg/d
In the Phase 2b portion of the study, PMF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP.
Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
Experimental: Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d
In the Phase 2b portion of the study, PPV-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP.
Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
Experimental: Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d
In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP.
Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
Experimental: Ph 2b PMF: Bomedemstat 0.6 mg/kg/d
In the Phase 2b portion of the study, PMF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP.
Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
Experimental: Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d
In the Phase 2b portion of the study, PPV-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP.
Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
Experimental: Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d
In the Phase 2b portion of the study, PET-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP.
Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator.
The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
|
Oral (capsule) administration according to dose allocation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Dose Limiting Toxicities (DLTs)
Time Frame: Up to Day 7 of the ITP
|
DLT was defined as any one of the following adverse events (AEs) that occured through Day 7 of the Initial Treatment Period (ITP) and was considered by the Investigator to be possibly, probably or definitely related to bomedemstat:
The number of participants with a DLT were reported. |
Up to Day 7 of the ITP
|
Number of Participants With Serious Adverse Events
Time Frame: Up to approximately 30 months
|
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related.
This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study.
Serious AEs (SAEs) were any AE that resulted in death, life-threatening experience, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly, or important medical events.
The number of participants with at least one treatment-emergent (TE) SAE was reported for each arm.
|
Up to approximately 30 months
|
Number of Participants With Adverse Events
Time Frame: Up to approximately 30 months
|
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related.
This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study.
The number of participants with at least one TE AE was reported for each arm.
|
Up to approximately 30 months
|
Number of Participants That Discontinued Study Treatment Due To AEs
Time Frame: Up to approximately 29 months
|
An AE was any undesirable physical, psychological or behavioral effect experienced by a participant, in conjunction with the use of the drug or biologic, whether or not product-related.
This included any untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat until completion of the study.
The number of participants that discontinued study treatment with bomedemstat due to a TE AE was reported for each arm.
|
Up to approximately 29 months
|
Phase 1/2a Portion: Observed Maximum Concentration (Cmax) of Bomedemstat
Time Frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
|
Cmax was defined as the maximum observed concentration after administration obtained directly from the concentration time profile.
Blood and plasma samples were collected at pre-specified timepoints to calculate Cmax in participants of the Phase 1/2a portion of the study.
As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
|
Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
|
Phase 1/2a Portion: Time to Maximum Concentration (Tmax) of Bomedemstat
Time Frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
|
Tmax was defined as the time to maximum concentration after administration obtained by inspection.
Blood and plasma samples were collected at pre-specified timepoints to calculate Tmax in participants of the Phase 1/2a portion of the study.
As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
|
Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
|
Phase 1/2a Portion: Area Under the Concentration-time Curve of Bomedemstat From Time 0 to 24 Hours Post-dose (AUC0-24)
Time Frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
|
AUC0-24 was defined as the area under the concentration versus time curve calculated using the linear trapezoidal rule from the zero time-point to the 24-hour time-point concentration.
Blood and plasma samples were collected at pre-specified timepoints to calculate AUC0-24 in participants of the Phase 1/2a portion of the study.
As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
|
Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
|
Phase 1/2a Portion: Apparent Total Clearance (CL/F) of Bomedemstat After Oral Administration
Time Frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
|
CL/F was defined as the apparent total clearance of drug after oral administration.
Blood and plasma samples were collected at pre-specified timepoints to calculate CL/F in participants of the Phase 1/2a portion of the study.
As pre-specified by the protocol and Pharmacokinetic Analysis Plan (PAP), Phase 2b participants were excluded from this analysis.
|
Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
|
Percentage Change From Baseline in Spleen Volume
Time Frame: Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337)
|
Change in spleen volume was assessed based on calculated spleen volume (ml) measured by magnetic resonance imaging (MRI), or computerized tomography (CT) scan (where locally permitted) if the participant was not a candidate for MRI from Day 0. Percentage change from baseline in spleen volume was reported at Initial Treatment Period (ITP) Day 84, ITP Day 168, Additional Treatment Period 1 (ATP1) Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337).
|
Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337)
|
Percentage Change From Baseline in Spleen Size
Time Frame: Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591)
|
Change in spleen size was assessed based on spleen palpation (in cm) at each visit.
Percentage change from baseline in spleen size was reported at ITP Day 84, ITP Day 168, ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591).
As prespecified by the Statistical Analysis Plan, assessments for the Phase 1/2 groups were summarized using visit windowing after the Day 84 visit of the ITP to allow for comparison with the Phase 2b groups at ITP Day 168.
|
Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Concentration (performed in Phase 1/2a only)
Time Frame: Up to 3 months.
|
as measured by Cmin sampling.
|
Up to 3 months.
|
Spleen Volume
Time Frame: Baseline to each visit where the variable is measured.
|
Reduction in spleen volume based on MRI (or CT)
|
Baseline to each visit where the variable is measured.
|
Collaborators and Investigators
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Primary Myelofibrosis
- Thrombocytosis
- Thrombocythemia, Essential
- Polycythemia Vera
- Polycythemia
Other Study ID Numbers
- IMG-7289-CTP-102 (Other Identifier: Imagobio)
- 2018-003811-23 (EudraCT Number)
- MK-3543-002 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelofibrosis
-
Assaf-Harofeh Medical CenterUnknownMyelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ETIsrael
-
Centre Hospitalier Annecy GenevoisCompleted
-
AbbVieRecruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
-
AbbVieTerminatedMyelofibrosis (MF)United States, Korea, Republic of, South Africa
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan
-
The University of Hong KongRecruitingMyelofibrosis | Primary Myelofibrosis, Prefibrotic StageHong Kong
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingModerate and High Risk MyelofibrosisChina
-
Telios Pharma, Inc.RecruitingPrimary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET MyelofibrosisSpain, United States, France, Poland, Italy, Germany
Clinical Trials on Bomedemstat
-
Merck Sharp & Dohme LLCNot yet recruitingPrimary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis
-
The University of Hong KongImago BioSciences,Inc.Recruiting
-
Imago BioSciences, Inc., a subsidiary of Merck...CompletedEssential ThrombocythemiaUnited States, Australia, New Zealand, United Kingdom, Hong Kong, Germany, Italy
-
Imago BioSciences, Inc., a subsidiary of Merck...Active, not recruitingPolycythemia VeraUnited States, Australia, United Kingdom
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Imago BioSciences, Inc., a subsidiary of Merck...Active, not recruitingPrimary Myelofibrosis | Thrombocythemia, EssentialUnited States, Australia, Hong Kong, Germany, Italy, New Zealand, United Kingdom
-
Imago BioSciences, Inc., a subsidiary of Merck...CompletedAcute Myeloid Leukemia | Myelodysplastic SyndromeAustralia
-
Merck Sharp & Dohme LLCRecruitingEssential ThrombocythemiaIsrael, Australia, Hong Kong, Japan, New Zealand, Taiwan
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...SuspendedExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States